GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
GO:005105221 | Liver | HCC | regulation of DNA metabolic process | 198/7958 | 359/18723 | 7.62e-07 | 1.17e-05 | 198 |
GO:200102021 | Liver | HCC | regulation of response to DNA damage stimulus | 128/7958 | 219/18723 | 1.31e-06 | 1.90e-05 | 128 |
GO:0098813 | Liver | HCC | nuclear chromosome segregation | 157/7958 | 281/18723 | 3.82e-06 | 4.95e-05 | 157 |
GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
GO:005105411 | Liver | HCC | positive regulation of DNA metabolic process | 113/7958 | 201/18723 | 5.76e-05 | 5.33e-04 | 113 |
GO:200102211 | Liver | HCC | positive regulation of response to DNA damage stimulus | 64/7958 | 105/18723 | 1.03e-04 | 8.88e-04 | 64 |
GO:00062824 | Liver | HCC | regulation of DNA repair | 74/7958 | 130/18723 | 6.27e-04 | 3.89e-03 | 74 |
GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
GO:00457393 | Liver | HCC | positive regulation of DNA repair | 43/7958 | 73/18723 | 3.43e-03 | 1.55e-02 | 43 |
GO:2000779 | Liver | HCC | regulation of double-strand break repair | 47/7958 | 85/18723 | 1.17e-02 | 4.28e-02 | 47 |
GO:00070592 | Oral cavity | OSCC | chromosome segregation | 206/7305 | 346/18723 | 5.82e-15 | 3.76e-13 | 206 |
GO:005105210 | Oral cavity | OSCC | regulation of DNA metabolic process | 207/7305 | 359/18723 | 4.45e-13 | 2.17e-11 | 207 |
GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
GO:005105414 | Oral cavity | OSCC | positive regulation of DNA metabolic process | 126/7305 | 201/18723 | 8.12e-12 | 3.01e-10 | 126 |
GO:00002801 | Oral cavity | OSCC | nuclear division | 237/7305 | 439/18723 | 9.62e-11 | 2.90e-09 | 237 |
GO:00988132 | Oral cavity | OSCC | nuclear chromosome segregation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:200102017 | Oral cavity | OSCC | regulation of response to DNA damage stimulus | 131/7305 | 219/18723 | 3.21e-10 | 8.72e-09 | 131 |
GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZCWPW1 | SNV | Missense_Mutation | | c.334N>G | p.Leu112Val | p.L112V | Q9H0M4 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZCWPW1 | SNV | Missense_Mutation | novel | c.1002N>A | p.Met334Ile | p.M334I | Q9H0M4 | protein_coding | tolerated(0.15) | possibly_damaging(0.699) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
ZCWPW1 | SNV | Missense_Mutation | novel | c.1556C>T | p.Ser519Phe | p.S519F | Q9H0M4 | protein_coding | deleterious(0) | benign(0.387) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZCWPW1 | SNV | Missense_Mutation | | c.1103C>A | p.Ser368Tyr | p.S368Y | Q9H0M4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZCWPW1 | SNV | Missense_Mutation | novel | c.55T>G | p.Phe19Val | p.F19V | Q9H0M4 | protein_coding | deleterious(0) | possibly_damaging(0.573) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZCWPW1 | SNV | Missense_Mutation | | c.759N>G | p.Cys253Trp | p.C253W | Q9H0M4 | protein_coding | deleterious(0.03) | benign(0.43) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ZCWPW1 | SNV | Missense_Mutation | | c.593N>A | p.Ser198Tyr | p.S198Y | Q9H0M4 | protein_coding | tolerated(0.39) | benign(0.084) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZCWPW1 | SNV | Missense_Mutation | novel | c.548C>T | p.Thr183Ile | p.T183I | Q9H0M4 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
ZCWPW1 | SNV | Missense_Mutation | rs763310132 | c.1621C>T | p.Pro541Ser | p.P541S | Q9H0M4 | protein_coding | tolerated(0.06) | benign(0.021) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ZCWPW1 | SNV | Missense_Mutation | | c.1801A>G | p.Ser601Gly | p.S601G | Q9H0M4 | protein_coding | deleterious(0.02) | benign(0.058) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |